There have been 13 placebo-controlled trials of statins in 1683 children with dyslipidemias and normal kidney function. This recommendation does not apply to children with severely elevated LDL-C, and therapeutic lifestyle changes should be adopted among all children with CKD. As for all weak recommendations, practitioners should consider the clinical circumstances, patient s age, and preferences when considering an individual patient and his lifetime risk for atherosclerotic cardiovascular disease events with potential exposure to high LCL-C. Treatment strategies based on lifetime risk are problematic because of the lack of data on the long-term follow-up of randomized clinical trials 415 years in the general population, the safety, and event reduction when statins are used for periods 410 years, especially in individuals o40 years of age. Chapters 5 and 6 | Triglyceride-lowering treatment in adults and in children Grade 2D 5.1: In adults with CKD (including those treated with chronic dialysis or kidney transplantation) and hypertriglyceridemia, we suggest that therapeutic lifestyle changes be advised 2D 6.1: In children with CKD (including those treated with chronic dialysis or kidney transplantation) and hypertriglyceridemia, we suggest that therapeutic lifestyle changes be advised NO RECOMMENDATION FOR PHARMACOLOGICAL TREATMENT OF HIGH TGS IN ADULTS COULD BE MADE A meta-analysis of data from 18 randomized trials involving 45,058 participants drawn from the general population (i.e., not specific to CKD) demonstrated a modest 10% relative risk reduction in major cardiovascular events and a 13% relative risk reduction in coronary events for fibrate therapy.38 Too few participants with eGFR o60 ml/min per 1.73 m2 were included in either FIELD (The Fenofibrate Intervention and Event Lowering in Diabetes) or ACCORD-Lipid (Action to Control Cardiovascular Risk in Diabetes-Lipid) to provide reliable information on either the safety or efficacy of fenofibrate in this group. 